Patents by Inventor Alan Remaley

Alan Remaley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010601
    Abstract: The disclosure provides methods of synthesizing very long chain fatty acids, including deuterated very long chain fatty acids. The fatty acids can by polyunsaturated fatty acids. The methods include the step of reacting a protected leaving group (L)-substituted saturated aliphatic group with a halo-substituted unsaturated aliphatic group to form a protected aliphatic group. The protected aliphatic group is deprotected to form an alcohol. The alcohol is then oxidized, thereby forming a very long chain fatty acid.
    Type: Application
    Filed: August 31, 2021
    Publication date: January 11, 2024
    Inventors: Rolf SWENSON, Alan REMALEY, Zhen-Dan SHI, Zhi-hong YANG
  • Patent number: 11696941
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: July 11, 2023
    Assignees: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM RAINFOREST INNOVATIONS
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Patent number: 11633471
    Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 25, 2023
    Assignees: UNM Rainforest Innovations, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bryce Chackerian, Alan Remaley, Marcelo Amar, Alexandra Fowler
  • Publication number: 20230024795
    Abstract: Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
    Type: Application
    Filed: September 19, 2022
    Publication date: January 26, 2023
    Inventors: James D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
  • Patent number: 11467171
    Abstract: Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: October 11, 2022
    Inventors: James D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
  • Publication number: 20210236608
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 5, 2021
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Patent number: 10925938
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: February 23, 2021
    Assignees: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM Rainforest Innovations
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Publication number: 20200397891
    Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 24, 2020
    Inventors: Bryce Chackerian, Alan Remaley, Marcelo Amar, Alexandra Fowler
  • Publication number: 20190145990
    Abstract: Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 16, 2019
    Inventors: James D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
  • Publication number: 20190134170
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 9, 2019
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Patent number: 10279019
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 7, 2019
    Assignee: STC.UNM
    Inventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
  • Publication number: 20170189503
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Application
    Filed: February 11, 2015
    Publication date: July 6, 2017
    Inventors: Alan Remaley, John T. Schillerr, Marcelo Amar, Bryce Chackerian
  • Publication number: 20160074473
    Abstract: The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-? HDL, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines TNF-?, IL-1?, and/or IL-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed.
    Type: Application
    Filed: July 31, 2015
    Publication date: March 17, 2016
    Applicants: Kinemed, Inc., THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Scott TURNER, Anna Schwendeman, Alan Remaley
  • Patent number: 7378274
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 27, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Marie-Fran├žoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo
  • Patent number: 6846636
    Abstract: The present invention provides an isolated mammalian receptor which specifically binds a high density lipoprotein holoparticle, comprising a subunit of approximately 45-600 kDa molecular weight and one or more subunits selected from the group consisting of a subunit of approximately 40-50 kDa molecular weight, a subunit of approximately 120 kDa molecular weight and a subunit of approximately 400 kDa molecular weight.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: January 25, 2005
    Assignees: American National Red Cross, The United States of America as represented by the Department of Health and Human Services, MUSC Foundation for Research Development
    Inventors: William S. Argraves, Samar Hammad, Steingrimur Stefansson, Bryan Brewer, Alan Remaley
  • Publication number: 20020146792
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis.
    Type: Application
    Filed: May 2, 2001
    Publication date: October 10, 2002
    Inventors: Marie-Francoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo